Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 9/20 | 0.54 |
| ▸ | FPR1 | P21462 | 8/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687136 | 0.89 | FPR2 (0.50) | FPR2FPR1TSHRNPSR1GAA | |
| SCHEMBL2685671 | 0.87 | SCN9A (0.51) | FPR2FPR1KMT2A | |
| SCHEMBL2685669 | 0.87 | SCN9A (0.51) | FPR2FPR1KMT2A | |
| SCHEMBL2685377 | 0.86 | FPR2 (0.49) | FPR2FPR1TSHRNPSR1GAA | |
| SCHEMBL2685400 | 0.84 | DPP4 (0.48) | FPR2FPR1TSHRNPSR1USP30 | |
| SCHEMBL2685396 | 0.84 | DPP4 (0.48) | FPR2FPR1TSHRNPSR1USP30 | |
| SCHEMBL3793422 | 0.84 | EP300 (0.49) | FPR2FPR1TSHRNPSR1GAA | |
| SCHEMBL2685052 | 0.84 | EP300 (0.49) | FPR2FPR1TSHRNPSR1GAA | |
| Hydrochloric Acid SCHEMBL2686718 | 0.83 | HDAC8 (0.50) | FPR2FPR1TSHRNPSR1USP30 | |
| SCHEMBL2684655 | 0.83 | FPR2 (0.65) | FPR2FPR1TSHRNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | FPR2 1040/4885FPR1 1961/4885TSHR 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.